Aurora Cannabis Inc SEC filings ACB
Aurora Cannabis Inc has 431 filings in SEC EDGAR's recent list, going back to Aug 31, 2016. Its latest annual report, Form 40-F, was filed on Jun 11, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Nov 4, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 40-F | Annual report (Canadian issuer) | Jun 11, 2026 | Mar 31, 2026 |
| 40-F | Annual report (Canadian issuer) | Jun 18, 2025 | Mar 31, 2025 |
| 40-F | Annual report (Canadian issuer) | Jun 20, 2024 | Mar 31, 2024 |
| 40-F | Annual report (Canadian issuer) | Jun 14, 2023 | Mar 31, 2023 |
| 40-F | Annual report (Canadian issuer) | Sep 21, 2022 | Jun 30, 2022 |
| 40-F | Annual report (Canadian issuer) | Sep 27, 2021 | Jun 30, 2021 |
| 40-F | Annual report (Canadian issuer) | Sep 25, 2020 | Jun 30, 2020 |
| 40-F/A | Amended annual report (Canadian issuer) | Mar 27, 2020 | Jun 30, 2019 |
| 40-F/A | Amended annual report (Canadian issuer) | Sep 13, 2019 | Jun 30, 2019 |
| 40-F | Annual report (Canadian issuer) | Sep 11, 2019 | Jun 30, 2019 |
Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- ACB (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Edmonton, Alberta, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1683541
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.